Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Light AI
Vancouver, British Columbia, Canada
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Light AI’s patented, app-based solution demonstrated 96.6% accuracy and 100% negative predictive value (NPV) in pre-FDA validation studies for differentiating between Group A Streptococcus and viral pharyngitis, matching the 'gold standard' swab culture for Group A Streptococcus diagnosis. Technology is being prepared for expanded clinical trials and pilot rollouts in Africa and emerging markets.[3]
- Therapeutic areas
- Infectious Diseases
- Modalities
- DeviceNon-pharmacological therapyDigital diagnostics
- Industry
- Digital Health Medical Devices
02
Partnerships
ELIQUENT Life SciencesEmergo (regulatory consulting/quality management)[3]International trials and outreach partners in Africa and India[1][3][4]
Beyond the preview
Go deeper on Light AI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Light AI.